---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-23-003720"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:17:37.187301+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precigen reports Q4 2022 loss of $22.2M; cash $99.7M; clinical progress in RRP and AML

## Summary
- Q4 loss from continuing ops $22.2M ($0.11/sh); full year loss $79.8M ($0.40/sh).
- Cash, equivalents, short-term investments, restricted cash $99.7M as of Dec 31, 2022.
- Divested Trans Ova Genetics for $162.3M net; retired $156.7M of convertible notes in 2022.
- Jan 2023 public offering raised ~$73M net from 44M shares at $1.75/sh.
- Positive Phase 1 data: PRGN-2012 in RRP (50% complete response) and PRGN-3006 in AML (27% ORR).

## SEC filing metadata
- accession: 0000950103-23-003720
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/0000950103-23-003720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/dp190237_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-23-003720
- JSON: https://secwatch.observer/filing/0000950103-23-003720.json
- Plain text: https://secwatch.observer/filing/0000950103-23-003720.txt

## Key facts
- Earnings Releases
  PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 6, 2023, reporting its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/0000950103-23-003720-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.